Cited 0 times in
Retinal Vascular Occlusion Risks in High Blood Pressure and the Benefits of Blood Pressure Control
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성수 | - |
dc.contributor.author | 김용준 | - |
dc.contributor.author | 변석호 | - |
dc.contributor.author | 이승규 | - |
dc.date.accessioned | 2023-07-12T02:58:19Z | - |
dc.date.available | 2023-07-12T02:58:19Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 0002-9394 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195455 | - |
dc.description.abstract | PURPOSE: This study aimed to evaluate the association of retinal vascular occlusion, including retinal vein occlusion (RVO) and retinal artery occlusion (RAO), with stages of hypertension. DESIGN: Nationwide, population-based retrospective cohort study. METHODS: Based on baseline blood pressure (BP) as defined by the 2017 American College of Cardiology/American Heart Association guideline, participants were categorized into 4 BP groups. For the BP change measurement, BP groups were defined based on the combination of baseline and follow-up BP categories. The composite retinal vascular occlusion events and hazard ratios (HRs) of retinal vascular occlusion according to BP groups were estimated. RESULTS: With normal BP as the reference, multivariate-adjusted HRs for retinal vascular occlusion were significantly higher than in other BP groups, showing much higher HRs in stage 2 hypertension than in stage 1 (HR, 1.10 for elevated BP; 1.07 for stage 1 hypertension; and 1.32 for stage 2 hypertension). Individual disease analysis showed consistent statistical significance in RVO, whereas RAO showed nonsignificant results. Lowering BP significantly decreased the HRs of retinal vascular occlusion in both stage 1 and stage 2 hypertension (HR, 0.88 and 0.73, respectively). However, once hypertension was diagnosed, the risk of retinal vascular occlusion was higher compared to that in the normal BP groups. CONCLUSIONS: Elevated BP, stage 1 hypertension, and stage 2 hypertension were all associated with higher retinal vascular occlusion risks than was normal BP. Controlling hypertension appears to reduce the risk of subsequent retinal vascular occlusion; however, the incidence rate was still be significantly higher than that in persons who maintained a normal BP. © 2023 Elsevier Inc. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Retinal Vascular Occlusion Risks in High Blood Pressure and the Benefits of Blood Pressure Control | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학교실) | - |
dc.contributor.googleauthor | Hae Rang Kim | - |
dc.contributor.googleauthor | Nang Kyeong Lee | - |
dc.contributor.googleauthor | Christopher Seungkyu Lee | - |
dc.contributor.googleauthor | Suk Ho Byeon | - |
dc.contributor.googleauthor | Sung Soo Kim | - |
dc.contributor.googleauthor | Seung Won Lee | - |
dc.contributor.googleauthor | Yong Joon Kim | - |
dc.identifier.doi | 10.1016/j.ajo.2023.01.023 | - |
dc.contributor.localId | A00571 | - |
dc.contributor.localId | A05821 | - |
dc.contributor.localId | A01849 | - |
dc.contributor.localId | A02913 | - |
dc.relation.journalcode | J00097 | - |
dc.identifier.eissn | 1879-1891 | - |
dc.identifier.pmid | 36736752 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S000293942300039 | - |
dc.contributor.alternativeName | Kim, Sung Soo | - |
dc.contributor.affiliatedAuthor | 김성수 | - |
dc.contributor.affiliatedAuthor | 김용준 | - |
dc.contributor.affiliatedAuthor | 변석호 | - |
dc.contributor.affiliatedAuthor | 이승규 | - |
dc.citation.volume | 250 | - |
dc.citation.startPage | 111 | - |
dc.citation.endPage | 119 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF OPHTHALMOLOGY, Vol.250 : 111-119, 2023-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.